4SC has reported the positive results from a Phase IIb clinical trial of vidofludimus in patients with rheumatoid arthritis.

The randomised, double-blind, placebo-controlled Phase IIb trial included 236 patients and demonstrated the drug to be safe and well tolerated.

The data also indicated that the drug improved clinical response with no changes in adverse events compared to a placebo.